DRKS00024559已完成未知
Incremental infusion of atrial natriuretic peptide suppresses leptin secretion in healthy men.
Deutsches Zentrum für Luft- und Raumfahrt (DLR)Institut für Luft- und Raumfahrtmedizin0 个研究点目标入组 17 人开始时间: 2021年6月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 20 Years 至 40 Years（—）
- 性别
- Male
入选标准
- •BMI 20-25 kg/m2
- •No medication
排除标准
- •BMI < 20 or > 25 kg/m2
- •Any medication
研究者
相似试验
已完成
不适用
ow dose atrial natriuretic peptide provides effective renal protection from acute kidney injury after aortic arch surgery: a randomised controlled trialacute kidney injuryJPRN-UMIN000011650Kawasaki Saiwai Hospital43
已完成
不适用
Phase 1 study of human atrial natriuretic peptide during perioperative period for completely resected colorectal cancerColorectal cancerJPRN-UMIN000025877Osaka University Graduate School of Medicine5
已完成
2 期
Human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trialnon-small cell lung cancerJPRN-UMIN000018480ational Cerebral and Cardiovascular Center332
已完成
不适用
Efficacy of human atrial natriuretic peptide for the patients with severe sepsis; Impact on prevention against acute kidney injurySevere sepsisJPRN-UMIN000003821Tosei General Hospital60
已完成
不适用
sing Brain-Natriuretic Peptide (blood test for heart failure) and the San Francisco Syncope Rule to reduce hospital admissions for fainting.SyncopeACTRN12612000489897Karen Shakespeare450